Entero Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
Entero Therapeutics, Inc. is seeking shareholder approval for a reverse stock split to address Nasdaq's minimum bid price requirement, alongside proposals for director elections, executive compensation, and auditor ratification at its upcoming virtual Annual Meeting on June 30, 2025.
Entero Therapeutics finalizes its merger with ImmunogenX and provides pro forma financial statements reflecting the combined operations.
First Wave BioPharma finalizes the acquisition of ImmunogenX in an all-stock transaction, gaining a Phase 3-ready asset, latiglutenase, for celiac disease and strengthening its GI-focused pipeline.
First Wave BioPharma finalizes the acquisition of ImmunogenX in an all-stock transaction, adding latiglutenase, a promising celiac disease treatment, to its late-stage GI-focused clinical pipeline.